Flow cytometry in Developing Cell-Based Potency Assays for AAV Gene Therapies

 

INTRODUCTION

Adeno-Associated Virus (AAV) mediated gene therapy is rapidly advancing as new clinidal trials are beginning for the treatment of multiple diseases.  As a result there is an increasing need to develop assays that meet FDA requirements to move programs into the clinic.  Flow cytometry is a powerful tool used in developing cell -based potency assays for advancing multiple drug modalities including Adeno-Associated Virus (AAV) mediated gene therapy.

Potency assays play a critical role in drug development, particularly for biopharmaceuticals and advanced therapy medicinal products. They are essential for several reasons including Regulatory Requirement, Quality Control, Clinical Trial Support, and Product Characterization.  Early development and validation of these assays can significantly impact the success of drug candidates, particularly in the field of advanced therapies such as Adeno-Associated Virus (AAV).

Flow cytometry has emerged as a powerful platform for developing potency assays for AAV vectors in gene therapy applications. The ability to quantitatively measure transduction efficiency, transgene expression, and functional activity makes flow cytometry particularly valuable for regulatory compliance and batch release testing of AAV products. This report examines key strategies, challenges, and practical approaches for developing robust cell-based potency assays using flow cytometry.

APPLICATION OF FLOW CYTOMETRY IN AAV POTENCY ASSAYS

 AAV mediated gene delivery is becoming an important therapeutic modality. Potential medical conditions that are amenable to AAV therapy include vision defects, abnormal clotting function, oncology care, and gene-related metabolic function.   Flow cytometry offers unique advantages for potency assessment due to its ability to simultaneously measure multiple parameters at the single-cell level, including protein expression, cell viability, and functional outcomes.

Flow cytometry enables the evaluation of AAV transduction efficiency by quantifying transgene-positive cells with high specificity and precision, providing a direct measure of the vector’s functional activity. It is particularly valuable for analyzing recombinant AAVs that encode fluorescent proteins or viral proteins detectable via fluorescence-labeled antibodies. Compared to traditional analytical methods, flow cytometry can identify discrete, rare target populations not readily detectable through other techniques, making it essential for comprehensive potency determination. Case studies have demonstrated flow cytometry’s flexibility in implementing cell-based potency assays for various applications including mRNA vaccines, AAVs, and plasmids, establishing functional relationships to therapeutic mechanisms of action. Flow cytometry is pivotal for assessing the biological activity of AAV vectors by quantifying transduction efficiency and transgene expression at the single-cell level.

ADVANTAGES OF FLOW CYTOMETRY FOR AAV POTENCY TESTING

 Flow cytometry has several significant potential advantages as a platform for AAV potency assays. One immediate advantage is the ability to measure transduction efficiency directly.  In addition, it is possible to generate multiple data sets from a singular readout which is valuable when it is necessary to test several parameters simultaneously.  Such an approach can establish a functional relationship to the therapeutic mechanism of action.

Some examples of flow cytometry potency assays used for AAV include:

  • AAV8 vectors expressing Factor IX in hepatocytes analyzed via flow cytometry, which correlated with therapeutic potency.
  • Validating the therapeutic drug Luxturna (voretigene neparvovec), an AAV gene therapy approved by the FDA to treat inherited retinal diseases (IRDs).
  • Correcting metabolic gene defects such as Uracil diphosphate-Glucuronosyltransferase (UGT).

STRATEGIES FOR DEVELOPING CELL-BASED POTENCY ASSAYS FOR AAV VECTORS BY FLOW CYTOMETRY

 A flow chart showing cell-based potency assay development using flow cytometry.

 

A flow chart showing cell-based potency assay development using flow cytometry.

Multiple parameters can be tested for ultimately developing a cell-based potency assay for AAV mediated gene delivery.

A.  Cell Line Selection and Optimization

Selecting appropriate cell lines is a critical first step in developing effective potency assays for AAV vectors. Different AAV serotypes demonstrate varying transduction efficiencies across cell types, requiring careful optimization.

The selection of cell lines that are permissive to specific AAV serotypes significantly impacts assay sensitivity. Research shows that AAV serotypes exhibit distinct cellular tropism patterns. For example, studies have demonstrated that HEK293 cells are highly permissive to AAV2, achieving transduction efficiencies of 71% at two days post-transduction. In contrast, AAV8 and AAV5 often demonstrate lower in vitro transduction efficiency in standard cell lines.

For AAV serotypes that show poor transduction in commonly used cell lines, researchers have explored alternative options. For instance, when testing AAV5 and AAV8 vectors, CHO-K1 and Huh-7 cells respectively have demonstrated better gene transfer efficiency compared to HEK293 cells. This highlights the importance of screening multiple cell lines to identify the most suitable option for each AAV serotype.

B.  Flow Cytometry Assay Design and Optimization

Developing a flow cytometry-based potency assay requires careful consideration of multiple parameters including reporter systems, antibody selection, and transduction conditions.

Antibody-based detection methods: For transgene products that lack inherent fluorescence, antibody-based detection methods provide an effective alternative. A validated example involves using monoclonal antibodies to detect intracellular expression of the transgene.

Transduction optimization strategies: Optimizing transduction conditions is essential for maximizing assay sensitivity and reproducibility. Several strategies have proven effective such as increasing the amount of time used for transduction. Another important factor is multiplicity of infection (MOI).  Establishing the appropriate MOI range is critical for assay linearity.

C.  Validation Parameters (GLP/GMP) for Flow Cytometry-based Potency Assays

 For GMP compliance, flow cytometry-based potency assays must be validated for the following parameters:

  • Accuracy: Measure how close test results come to the true value.
  • Precision: Intra-assay and inter-day precision are critical parameters. In one study, the intra-assay coefficient of variation (CV%) for the highest vector dose varied from 1.3% to 18.4%, with an average of 11.0%. The inter-day CV% for the same dose was 22.6%.
  • Specificity: Demonstrate that the assay measures the intended analyte without interference from other components.
  • Linearity/Range: Establish a range within which the assay produces results proportional to the concentration of analyte. For example, researchers demonstrated linear GFP expression from 6.4 × 10^1 to 8 × 10^3 vg/cell of AAV2 and from 1.6 × 10^3 to 1 × 10^6 vg/cell of AAV9.
  • Robustness: Evaluate the assay’s capability to remain unaffected by small but deliberate variations in method parameters.
  • System Suitability: Establish criteria that demonstrate the assay is working properly at the time of use.

D.  Regulatory Requirements for Flow Cytometry-Based Potency Assays

Regulatory agencies require well-developed potency assays for approval of AAV products. For Phase I and II clinical trials, qualified in vitro potency release assays may be appropriate , while fully validated, cGMP-compliant assays are necessary for Phase III and Biologics License Application (BLA) approval. The assay should also establish a clear relationship to the product’s mechanism of action.

A flow chart showing GMP validation of flow cytometry-based potency assays

A flow chart showing GMP validation of flow cytometry-based potency assays

CONCLUSION

Flow cytometry represents a powerful platform for developing cell-based potency assays for AAV vectors, offering advantages in sensitivity, selectivity, and the ability to generate multiple data points from a single readout. Successful implementation requires careful consideration of cell line selection, reporter systems, transduction conditions, and validation parameters.

The strategies outlined in this report provide a roadmap for developing robust, sensitive, and reproducible flow cytometry-based potency assays for AAV vectors. By implementing these approaches, researchers and manufacturers can develop assays that not only meet regulatory requirements but also provide meaningful insights into vector potency that correlate with in vivo efficacy.  As AAV-based gene therapies continue to advance through clinical development and commercialization, well-designed potency assays will remain critical for ensuring product quality, consistency, and efficacy. Flow cytometry’s unique capabilities make it an increasingly valuable tool in this important aspect of gene therapy development.

 

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)